Literature DB >> 29564187

Approach and management of checkpoint inhibitor-related immune hepatitis.

Aravind Sanjeevaiah1,2, Thomas Kerr3, Muhammad Shaalan Beg1,2.   

Abstract

Immune checkpoint inhibitors have promising clinical activity across multiple gastrointestinal cancers and immune-mediated hepatotoxicity is particularly relevant for this group of patients. In this article we will review the recognition, workup and management of suspected checkpoint inhibitor related immune-hepatitis.

Entities:  

Keywords:  Immunotherapy; gastrointestinal cancers; immune checkpoint inhibitors; immune-mediated toxicity

Year:  2018        PMID： 29564187      PMCID： PMC5848041          DOI： 10.21037/jgo.2017.08.14

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN： 2078-6891


  20 in total

Review 1.  Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis of published data.

Authors:  Wenjun Wang; Puyi Lie; Minzhang Guo; Jianxing He
Journal:  Int J Cancer       Date:  2017-06-20       Impact factor: 7.396

2.  Ipilimumab-associated Hepatitis: Clinicopathologic Characterization in a Series of 11 Cases.

Authors:  Melanie Johncilla; Joseph Misdraji; Daniel S Pratt; Agoston T Agoston; Gregory Y Lauwers; Amitabh Srivastava; Leona A Doyle
Journal:  Am J Surg Pathol       Date:  2015-08       Impact factor: 6.394

3.  Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1.

Authors:  Stéphane Champiat; Laurent Dercle; Samy Ammari; Christophe Massard; Antoine Hollebecque; Sophie Postel-Vinay; Nathalie Chaput; Alexander Eggermont; Aurélien Marabelle; Jean-Charles Soria; Charles Ferté
Journal:  Clin Cancer Res       Date:  2016-11-08       Impact factor: 12.531

4.  Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.

Authors:  Michael A Postow; Jason Chesney; Anna C Pavlick; Caroline Robert; Kenneth Grossmann; David McDermott; Gerald P Linette; Nicolas Meyer; Jeffrey K Giguere; Sanjiv S Agarwala; Montaser Shaheen; Marc S Ernstoff; David Minor; April K Salama; Matthew Taylor; Patrick A Ott; Linda M Rollin; Christine Horak; Paul Gagnier; Jedd D Wolchok; F Stephen Hodi
Journal:  N Engl J Med       Date:  2015-04-20       Impact factor: 91.245

Review 5.  Management of immune-related adverse events and kinetics of response with ipilimumab.

Authors:  Jeffrey S Weber; Katharina C Kähler; Axel Hauschild
Journal:  J Clin Oncol       Date:  2012-05-21       Impact factor: 44.544

Review 6.  Immune checkpoint blockade for hematologic malignancies: a review.

Authors:  Matthew J Pianko; Yuzhou Liu; Srishti Bagchi; Alexander M Lesokhin
Journal:  Stem Cell Investig       Date:  2017-04-19

Review 7.  Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies.

Authors:  Steven J O'Day; Omid Hamid; Walter J Urba
Journal:  Cancer       Date:  2007-12-15       Impact factor: 6.860

8.  Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.

Authors:  Caroline Robert; Antoni Ribas; Jedd D Wolchok; F Stephen Hodi; Omid Hamid; Richard Kefford; Jeffrey S Weber; Anthony M Joshua; Wen-Jen Hwu; Tara C Gangadhar; Amita Patnaik; Roxana Dronca; Hassane Zarour; Richard W Joseph; Peter Boasberg; Bartosz Chmielowski; Christine Mateus; Michael A Postow; Kevin Gergich; Jeroen Elassaiss-Schaap; Xiaoyun Nicole Li; Robert Iannone; Scot W Ebbinghaus; S Peter Kang; Adil Daud
Journal:  Lancet       Date:  2014-07-15       Impact factor: 79.321

9.  Ipilimumab associated hepatitis: imaging and clinicopathologic findings.

Authors:  Kyung Won Kim; Nikhil H Ramaiya; Katherine M Krajewski; Jyothi P Jagannathan; Sree Harsha Tirumani; Amitabh Srivastava; Nageatte Ibrahim
Journal:  Invest New Drugs       Date:  2013-02-14       Impact factor: 3.850

10.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245
View more
  9 in total

1.  Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis.

Authors:  Michael Li; Jordan S Sack; Osama E Rahma; F Stephen Hodi; Stephen D Zucker; Shilpa Grover
Journal:  Cancer       Date:  2020-09-05       Impact factor: 6.860

2.  Incidence of Elevated Aminotransferases With or Without Bilirubin Elevation During Treatment With Immune Checkpoint Inhibitors: A Retrospective Study of Patients From Community Oncology Clinics in the United States.

Authors:  Christopher Kim; Shao Zhu; Hosein Kouros-Mehr; Sophia Khaldoyanidi
Journal:  Cureus       Date:  2022-04-11

Review 3.  Reactivation of hepatitis B virus infection in patients with hematologic disorders.

Authors:  Bo Wang; Ghulam Mufti; Kosh Agarwal
Journal:  Haematologica       Date:  2019-02-07       Impact factor: 9.941

4.  HBeAg seroconversion is associated with a more effective PD-L1 blockade during chronic hepatitis B infection.

Authors:  Sara Ferrando-Martinez; Kelly Huang; Angie Snell Bennett; Patricia Sterba; Li Yu; JoAnn A Suzich; Harry L A Janssen; Scott H Robbins
Journal:  JHEP Rep       Date:  2019-06-28

5.  Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience.

Authors:  Tiago de Castro; Leonie S Jochheim; Melanie Bathon; Sabrina Welland; Bernhard Scheiner; Kateryna Shmanko; Daniel Roessler; Najib Ben Khaled; Matthias Jeschke; Johannes M Ludwig; Jens U Marquardt; Arndt Weinmann; Matthias Pinter; Christian M Lange; Arndt Vogel; Anna Saborowski
Journal:  Ther Adv Med Oncol       Date:  2022-02-26       Impact factor: 5.485

Review 6.  Autoimmune liver diseases in systemic rheumatic diseases.

Authors:  Chrong-Reen Wang; Hung-Wen Tsai
Journal:  World J Gastroenterol       Date:  2022-06-21       Impact factor: 5.374

Review 7.  Immunotherapy for advanced hepatocellular carcinoma: From clinical trials to real-world data and future advances.

Authors:  Kathrine S Rallis; Dimitrios Makrakis; Ioannis A Ziogas; Georgios Tsoulfas
Journal:  World J Clin Oncol       Date:  2022-06-24

8.  Immunotherapy-related hepatitis: real-world experience from a tertiary centre.

Authors:  Vincent Cheung; Tarun Gupta; Miranda Payne; Mark R Middleton; Jane D Collier; Alison Simmons; Paul Klenerman; Oliver Brain; Jeremy F Cobbold
Journal:  Frontline Gastroenterol       Date:  2019-03-22

Review 9.  Liver damage related to immune checkpoint inhibitors.

Authors:  Naoshi Nishida; Masatoshi Kudo
Journal:  Hepatol Int       Date:  2019-01-03       Impact factor: 9.029
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.